Regeneron Form 144: 400-Share Resale Notice

Regeneron Pharmaceuticals filed a Form 144 notice for the proposed sale of 400 shares of Common Stock through J.P.

Rhea-AI Filing Summary

Regeneron Pharmaceuticals filed a Form 144 notice for the proposed sale of 400 shares of Common Stock through J.P. Morgan Securities LLC at its New York address. The filing also records a prior sale of 100 shares on 05/01/2026 for $70,523.79.

Insights

Securities Counsel

Routine affiliate resale notice for a small quantity of shares.

The filing is a Form 144 disclosure that lists 400 shares of Common Stock to be sold through J.P. Morgan Securities LLC. It also documents a prior sale of 100 shares on 05/01/2026 for $70,523.79.

Regulatory treatment is procedural: Form 144 notifies the market of an affiliate's intent to sell under exemptions. Timing, methods of sale, and net proceeds are not specified in the excerpt.

Key Figures

Shares proposed for resale: 400 shares Prior sale: 100 shares Value of prior sale: $70,523.79

3 metrics

Shares proposed for resale 400 shares Form 144 listing via J.P. Morgan Securities LLC

Prior sale 100 shares Sold on 05/01/2026

Value of prior sale $70,523.79 Proceeds reported for 100-share sale on 05/01/2026

Key Terms

Form 144, Compensation, Securities Sold During The Past 3 Months

3 terms

Form 144 regulatory

"144: Securities To Be Sold Common Stock"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Compensation financial

"Common Stock | 08/22/2013 | Compensation | Issuer"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months Arthur F. Ryan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the REGN Form 144 disclose?

It discloses a proposed resale of 400 shares of Regeneron common stock via J.P. Morgan and records a prior sale of 100 shares on 05/01/2026 for $70,523.79. This is a regulatory notice by an affiliate.

Who is the broker handling the proposed sale in the REGN filing?

J.P. Morgan Securities LLC at 270 Park Avenue, New York, is listed as the broker for the 400-share resale. The filing provides the broker's address and identifies the broker as the intermediary for the proposed transaction.

How many shares were previously sold by the reporting person?

The filing shows a prior sale of 100 shares by Arthur F. Ryan on 05/01/2026 with a reported transaction value of $70,523.79. That prior sale is recorded in the "Securities Sold During The Past 3 Months" section.

Does the Form 144 state how proceeds will be used?

The excerpt does not state use of proceeds. The filing lists the number of shares and broker but does not disclose proceeds allocation, timing, or specific sale mechanics in the provided text.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 05:46 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001187443
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Regeneron Pharmaceuticals, Inc.
SEC File Number	000-19034
Address of Issuer	777 Old Saw Mill River Road Tarrytown New York NEW YORK 10591
Phone	914-847-7000
Name of Person for Whose Account the Securities are To Be Sold	Arthur F. Ryan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 270 Park Avenue 10th Floor New York NY 10017	400	249888	103020000	07/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/22/2013	Compensation	Issuer			400	08/22/2013	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Arthur F. Ryan C/o Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591	Common	05/01/2026	100	70523.79

144: Remarks and Signature

Remarks
Date of Notice	07/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	10/31/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Arthur F. Ryan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)